---
schema_version: "secwatch.filing_event.v1"
accession: "0001808805-24-000070"
form_type: "8-K"
ticker: "NAUT"
cik: "0001808805"
company_name: "Nautilus Biotechnology, Inc."
filed_at: "2024-10-29T23:59:59+00:00"
generated_at: "2026-05-30T09:22:15.925118+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# Nautilus Q3 net loss $16.4M, cash $221.2M; OpEx flat YoY at $19.1M

## Summary
- Net loss of $16.4M for Q3 2024, compared to $15.9M loss in Q3 2023.
- Operating expenses $19.1M, flat YoY; personnel cost increase offset by incentive accrual reduction.
- Cash, equivalents, and investments totaled $221.2M as of September 30, 2024.
- CEO notes positive researcher feedback for single-molecule proteome platform, no revenue reported.

## SEC filing metadata
- accession: 0001808805-24-000070
- form_type: 8-K
- ticker: NAUT
- cik: 0001808805
- company_name: Nautilus Biotechnology, Inc.
- filed_at: 2024-10-29T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1808805/000180880524000070/0001808805-24-000070-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1808805/000180880524000070/naut-20241029.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001808805-24-000070
- JSON: https://secwatch.observer/filing/0001808805-24-000070.json
- Plain text: https://secwatch.observer/filing/0001808805-24-000070.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.